MUSTANG BIO, INC.
MBIOMustang Bio is an American clinical-stage biopharmaceutical company founded in 2015 and headquartered in Worcester, MA, U.S. Operating as a partner company of Fortress Biotech, Mustang Bio develops CAR-T immunotherapies and gene therapies for multiple diseases, including hematologic cancers, solid tumors, and X-linked severe combined immunodeficiency (X-SCID).
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
No drugs found in this phase.
Frequently asked questions
When is MUSTANG BIO, INC.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for MUSTANG BIO, INC. (MBIO) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track MBIO biotech catalysts?→
Add MBIO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MUSTANG BIO, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.